Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

03 févr. 2026 16h05 HE | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT WORLDSYMPOSIUM 2026
03 févr. 2026 08h00 HE | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026

PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in...
27 janv. 2022 16h01 HE | Source: Freeline Therapeutics

Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™

LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
26 janv. 2021 07h00 HE | Source: Freeline Therapeutics

Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium™ 2021

LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...